Dr. Reddy’s Laboratories has been granted a patent for bicyclic heterocyclyl kinase enzyme inhibitor compounds, particularly IRAK4 inhibitors, useful in treating diseases mediated by kinase enzymes. The patent also covers pharmaceutical compositions containing these compounds. GlobalData’s report on Dr. Reddy’s Laboratories gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Dr. Reddy's Laboratories, Cancer treatment biomarkers was a key innovation area identified from patents. Dr. Reddy's Laboratories's grant share as of May 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11981685B2) discloses a compound selected from a specific group. The patent claims cover various aspects of this compound, including its form as a pharmaceutically acceptable salt. This compound shows promise in potential pharmaceutical applications, as indicated by the patent's focus on its pharmaceutical acceptability.
Furthermore, the patent specifies different variations of the compound, highlighting its versatility and potential for use in various formulations. By detailing the compound's characteristics and potential forms, the patent provides a comprehensive overview of its pharmaceutical applications. This patent grant underscores the significance of this compound in the field and opens up possibilities for further research and development in the pharmaceutical industry.
To know more about GlobalData’s detailed insights on Dr. Reddy's Laboratories, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.